BioForm Losses Much Improved – Analyst Blog
Zacks Market Commentaries (August 20th, 2009) Writes:
BioForm Medical, Inc. (BFRM) reported strong results for the fourth quarter of fiscal 2009. For the quarter, the loss per share was 4 cents, considerably better than the Zacks Consensus Estimate of 11 cents and the year-ago loss per share of 43 cents.
Quarterly results
Sales
Net sales in the quarter increased 15% year over year to $19.2 million. Growth was primarily due to higher revenues from the company’s main product, RADIESSE dermal filler. The product contributed $15.5 million of revenues in the U.S., increasing 17% year over year.
On a geographic basis, the U.S. contributed roughly 81% of total revenues and increased 17% year over year. The company’s international operations increased roughly 6% year over year.
Margins
Gross margin declined 1,010 basis points year over year to 76.2% in the quarter. The decline was due to a $1.4 million inventory write-off ...
Tags for this Post:
Aci, Analyst, Bioform Medical Inc, cent;, Market Commentary, plastic surgeries, Stocks to Watch, United States, USD, Zacks Market Commentaries
Aci, Analyst, Bioform Medical Inc, cent;, Market Commentary, plastic surgeries, Stocks to Watch, United States, USD, Zacks Market Commentaries


![[Most Recent Quotes from www.kitco.com]](http://www.kitconet.com/charts/metals/gold/t24_au_en_usoz_2.gif)
![[Most Recent Quotes from www.kitco.com]](http://www.kitconet.com/charts/metals/silver/t24_ag_en_usoz_2.gif)

Coal is not King today, that crown goes to oil. Peabody (NYSE:
